Canada Life’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11,784
| Closed | -$851K | – | 1870 |
|
|
2025
Q4 | $851K | Sell |
11,784
-10,563
| -47% | -$682K | ﹤0.01% | 1417 |
|
|
2025
Q3 | $951K | Buy |
22,347
+14,054
| +169% | +$568K | ﹤0.01% | 1455 |
|
|
2025
Q2 | $236K | Sell |
8,293
-13,465
| -62% | -$401K | ﹤0.01% | 1694 |
|
|
2025
Q1 | $644K | Buy |
21,758
+2,745
| +14% | +$85.5K | ﹤0.01% | 1556 |
|
|
2024
Q4 | $552K | Sell |
19,013
-1,376
| -7% | -$57.5K | ﹤0.01% | 1619 |
|
|
2024
Q3 | $938K | Hold |
20,389
| – | – | ﹤0.01% | 1531 |
|
|
2024
Q2 | $834K | Buy |
20,389
+11,737
| +136% | +$337K | ﹤0.01% | 1541 |
|
|
2024
Q1 | $221K | Hold |
8,652
| – | – | ﹤0.01% | 1817 |
|
|
2023
Q4 | $78K | Hold |
8,652
| – | – | ﹤0.01% | 1993 |
|
|
2023
Q3 | $55K | Buy |
8,652
+6,279
| +265% | +$54.1K | ﹤0.01% | 2058 |
|
|
2023
Q2 | $26K | Hold |
2,373
| – | – | ﹤0.01% | 2101 |
|
|
2023
Q1 | $36K | Buy |
2,373
+476
| +25% | +$10.5K | ﹤0.01% | 2114 |
|
|
2022
Q4 | $42K | Hold |
1,897
| – | – | ﹤0.01% | 2107 |
|
|
2022
Q3 | $31K | Hold |
1,897
| – | – | ﹤0.01% | 2181 |
|
|
2022
Q2 | $28K | Hold |
1,897
| – | – | ﹤0.01% | 2194 |
|
|
2022
Q1 | $37K | Hold |
1,897
| – | – | ﹤0.01% | 2229 |
|
|
2021
Q4 | $45K | Buy |
1,897
+967
| +104% | +$23.1K | ﹤0.01% | 2202 |
|
|
2021
Q3 | $23K | Hold |
930
| – | – | ﹤0.01% | 2403 |
|
|
2021
Q2 | $23K | Hold |
930
| – | – | ﹤0.01% | 2460 |
|
|
2021
Q1 | $20K | Hold |
930
| – | – | ﹤0.01% | 2507 |
|
|
2020
Q4 | $24K | Buy |
+930
| New | +$27.1K | ﹤0.01% | 2507 |
|
Other funds holding RNAM
Canada Life's RNAM Position: Q1 2026 in Review
Canada Life sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 11,784 shares — an estimated $851K sold.
Canada Life first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $951K in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Canada Life reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Canada Life sold 11,784 Avidity Biosciences shares in Q1 2026, an estimated $851K.
- Canada Life first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- Canada Life's Avidity Biosciences position peaked at $951K in Q3 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.